Clinical Trial

Diclofenac for Prevention of Post-ERC Pancreatitis

Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The study aims at assessing the effectiveness of Diclofenac for prevention of post-ERCP pancreatitis. It will be undertaken embedded in the Swedish national register for Gallstone surgery and ERCP (GallRiks). Patients are randomised to Diclofenac prior to the ERCP or no prophylaxis. GallRiks is used to identify which patients fulfill the eligibility criteria and which patients develop pancreatitis after the ERCP.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2018-07-11; most recent amendment 2025-08-12.
Trial Details
NCT Number NCT03595150
Lead Sponsor Karolinska Institutet
Collaborators: Uppsala University
Conditions Common Bile Duct Diseases
Enrollment 1,000 participants
Start Date 2026-01-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-13